



BRAWN



18F80

CIN NO.: L74899DL1985PLC022468

12th November, 2019

**The Deputy General Manager
Department of Corporate Relationship
BSE Limited,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001**

Scrip Code: 530207

Sub: Outcome of Board Meeting and Submission of Un-audited Financial Results for the quarter and half year ended 30.09.2019

Dear Sir/ Ma'am,

Pursuant to the Regulation 30 read with schedule III, Part A of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the company was held today i.e. 12th November, 2019 to consider and approve,

1. Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2019 and Statement of Assets & Liabilities as on that date.
2. Limited Review Report by the statutory Auditors of the company. The Board took note that the statutory auditors have expressed an unqualified and unmodified audit opinion.

The meeting of the Board of Directors commenced at 3:00 P.M. and concluded at 4:30 P.M.

Kindly take the same on record

For BRAWN BIOTECH LIMITED

**Priyanka Sharma
Company Secretary & Compliance Officer
Membership No. A50385**

Encl: As above

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

... for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48




BRAWN

BRAWN BIOTECH LIMITED							
CIN:L74899DL1905PLC022468							
REGD. OFFICE: 4B, Asaf Ali Road, II Floor, De lhi Stock Exchange Building, New Delhi 110002							
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER 2019							
Sr. No.	Particulars	Quarter Ended			Half yearly ended		Rs. In lacs
		30-Sep-19 Un-audited	30-Jun-19 Un-audited	30-Sep-18 Un-audited	30-Sep-19 Un-audited	30-Sep-18 Un-audited	Year Ended 31-Mar-19 Audited
1	Revenue from operations						
	Revenue from operations	1187.93	1,784.75	1,495.91	2,972.68	2,852.09	6,517.90
	Other Income	3.34	1.15	7.83	4.49	13.95	73.78
	Total Revenue	1,191.27	1,785.90	1,503.73	2,977.17	2,866.04	6,591.68
2	Expenses						
a	Cost of material consumed	-	-	-	-	-	-
b	Purchase of stock-in-trade	1011.81	1,599.66	1,347.14	2,611.48	2,539.38	5,848.92
c	Change in inventories of finished goods, work in progress and stock in trade	24.00	(17.04)	(7.75)	6.96	(0.65)	0.90
d	Employee Benefit expenses	55.04	52.86	54.98	107.90	112.70	302.49
e	Depreciation and amortisation expenses	0.80	0.79	0.81	1.59	1.60	3.20
f	Finance Cost	1.84	0.92	1.14	2.76	1.80	6.14
g	Other expenses	55.22	76.26	52.45	131.48	103.13	249.50
	Total Expenses	1,148.72	1,713.45	1,448.77	2,862.17	2,757.96	6,411.15
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	42.55	72.45	54.96	115.00	108.08	180.54
4	Other Income	-	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	42.55	72.45	54.96	115.00	108.08	180.54
6	Exceptional Items	-	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	42.55	72.45	54.96	115.00	108.08	180.54
8	Tax Expenses	8.55	18.74	15.65	27.28	31.49	47.24
9	Profit (Loss) for the period from continuing operations (7-8)	34.01	53.71	39.31	87.71	76.59	133.29
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	34.01	53.71	39.31	87.71	76.59	133.29
14	Other Comprehensive Income	(2.93)	(5.09)	1.31	(8.03)	5.13	5.53
	Total Comprehensive Income	31.07	48.62	40.62	79.69	81.72	138.82
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital						
	Face value of equity share capital						
16	Reserve excluding Revaluation Reserve						
17	Earnings per share						
i	Basic earnings per share	1.04	1.62	1.35	2.66	2.72	4.63
ii	Diluted earnings per share	1.04	1.62	1.35	2.66	2.72	4.63

NOTES:-

- Results for the quarter and half year ended on 30th September, 2019 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 12th November, 2019.
- The Statutory Auditors carried out the limited review for quarter and half year ended 30th September, 2019. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind AS 108 dealing with Operating Segments.
- The above Standalone Un-audited Financial Results for the quarter and half year ended on 30/09/2019 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited


Brij Raj Gupta
Director
DIN No. 01974969
Date: 12-11-2019
Place: Delhi

BRAWN BIOTECH LTD.
(Formerly Known as Brawn Pharmaceuticals Ltd.)

... for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462.
Email: solution@brawnbiotech.com Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram (Haryana) 122001. Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel: +91-8010416849/48



BRAWN

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468

Regd Office: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

Statement of Assets and Liabilities as on 30th September, 2019		
Particulars	Standalone	
	AS ON 30.09.2019 Un- audited Rupees in Lakhs	AS ON 31.03.2019 Audited Rupees in Lakhs
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	17.62	22.28
(b) Intangible Assets	-	-
(c) Financial Assets:		
(i) Trade Receivable	-	47.66
(ii) Loans	4.00	3.14
(e) Deferred tax assets (net)	6.28	8.00
(f) Other non-current assets	-	-
Sub Total Non Current Assets	27.91	81.08
Current assets		
(a) Inventories	26.90	34.76
(b) Financial Assets:		
(i) Trade receivables	1,805.23	1,505.42
(ii) Cash and cash equivalents	34.61	39.61
(iii) Bank balance other than (ii) above	-	-
(c) Other current financial assets	12.15	12.65
(d) Current Tax Assets(Net)	99.36	109.86
(e) Other Current Assets	287.61	473.85
Sub Total Current Assets	2,265.85	2,176.15
Total- Assets	2,293.76	2,257.23
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	300.03	300.03
(b) Other Equity	645.37	463.07
Total- Equity	945.40	763.10

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

... for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462.
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



BRAWN

CIN NO. L74032DL1903PLC022400

RAJIV DDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

Liabilities		
Non Current liabilities		
(a) Financial Liabilities		3.32
(i) Trade Payable	-	-
(ii) other financial liabilities	19.51	16.72
(b) Provisions	-	-
(c) Deferred tax liabilities (net)	-	-
Total Non Current Liabilities	19.51	20.05
Current Liabilities		
(a) Financial Liabilities		-
(i) Borrowings	-	1,122.85
(ii) Trade Payables	1,056.58	112.78
(b) other current financial liabilities	102.97	83.16
(c) Other Current Liability	35.52	43.95
(d) provisions	6.45	111.34
(e) current tax liabilities (net)	127.33	-
Total Current Liabilities	1,328.84	1,474.08
Total Equity and Liabilities	2,293.76	2,257.23

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Place : New Delhi
Date : 12-11-2019

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462.
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

To,
The Board of Directors of
Brawn Biotech Limited


We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited** for the period ended 30th September 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N


Rajeev Jain
Partner
Membership No. 099767
UDIN: 19099767AAAAFQ4129



Place: Delhi
Date: 12.11.2019